cardiovascular

Biotech

Lilly buys inflammation biotech Ventyx for $1.2B

Ventyx achieved its goal of securing Big Pharma commitment to its pipeline, with Lilly swooping in to buy the inflammation biotech for $1.2 billion.

James Waldron Jan 8, 2026 7:01am

graphic of a larger shark chomping up a smaller one

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm

Three knit hearts

Kardigan fashions $254M series B for late-stage pipeline

Oct 14, 2025 9:00am

Stethoscope and red heart with pink background

US VC launches another biotech with China-licensed asset

Sep 17, 2025 10:30am

A chessboard with blocks that read MA

Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2

Sep 9, 2025 4:28am

heart

Novartis returns to Argo for $5B cardiovascular collab

Sep 3, 2025 9:15am